Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan.
Acute heart failure
Cardiac rehabilitation
Disease management
Hospitalization outcomes
Journal
Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
11
2020
accepted:
18
01
2021
pubmed:
21
2
2021
medline:
21
2
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
This study described patients hospitalized for acute heart failure (AHF) in Japan who received intravenous (IV) diuretics and/or vasodilators as the initial therapy. The Japan Medical Data Vision database was used to identify adult patients hospitalized for AHF during 2013-2017, who were hemodynamically stable at presentation and treated with IV diuretics and/or IV vasodilators as initial therapy. Treatment patterns and use of cardiac rehabilitation, as well as outcomes (e.g., length of stay [LOS], in-hospital mortality, HF-readmission) were reported overall and by year of AHF hospitalization. Of 30,360 patients (mean age = 80.0 years; 52.2% male), 87.0% were treated during the hospitalization with IV diuretics, 63.9% with IV vasodilators, and 13.8% with intensified therapies. On average, the duration of IV therapy was 10.6 days. In-hospital cardiac rehabilitation was utilized by 51.7% of the patients for 11.7 days on average. Mean LOS was 23.3 days, while in-hospital mortality and 30-day HF readmission post-discharge were 13.2 and 9.5%, respectively. Hospitalization outcomes remained stable between 2013 and 2017 despite important changes in AHF management such as a decrease in carperitide use (55.9-40.0% in 2017), and increases in use of tolvaptan (from 14.2% in 2013 to 31.3% in 2017) and of cardiac rehabilitation (from 43.2% in 2013 to 56.1% in 2017). Patients with intensified therapies had the longest IV therapy duration (mean 23.8 days vs. 5.5-9.9 days), the highest cardiac rehabilitation services use (60.2 vs. 38.3-57.0%), the longest LOS (mean 36.7 vs. 16.3-22.2 days), and the highest in-hospital mortality (37.4 vs. 3.1-12.4%) compared to the other treatment groups. Contemporary treatment for AHF hospitalization in Japan comprises a long duration of IV therapy followed by extended use of oral medications and in-hospital cardiac rehabilitation prior to discharge. Patients requiring intensified therapies had much longer LOS and higher in-hospital mortality.
Identifiants
pubmed: 33609268
doi: 10.1007/s40119-021-00212-y
pii: 10.1007/s40119-021-00212-y
pmc: PMC8126582
doi:
Types de publication
Journal Article
Langues
eng
Pagination
211-228Références
Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep. 2017;14(5):385–92.
doi: 10.1007/s11897-017-0351-y
Tanaka TD, Sawano M, Ramani R, Friedman M, Kohsaka S. Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence. ESC Heart Fail. 2018;5(5):931–47.
doi: 10.1002/ehf2.12305
Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure- digest version. Circ J. 2019;83(10):2084–184.
doi: 10.1253/circj.CJ-19-0342
Gheorghiade M, Mebazaa A. Introduction to acute heart failure syndromes. Am J Cardiol. 2005;96(6A):1G-4G.
doi: 10.1016/j.amjcard.2005.07.014
Gheorghiade M, Mebazaa A. The challenge of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):86G-G89.
doi: 10.1016/j.amjcard.2005.07.026
Valente MA, Voors AA. Renal effects of vasodilators in acute heart failure. World J Cardiovasc Dis. 2013;3(02):8.
doi: 10.4236/wjcd.2013.32A002
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123–33.
doi: 10.1016/j.jacc.2013.11.053
Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008;52(20):1640–8.
doi: 10.1016/j.jacc.2008.07.056
Mentz RJ, Cotter G, Cleland JG, Stevens SR, Chiswell K, Davison BA, et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail. 2014;16(6):614–24.
doi: 10.1002/ejhf.92
Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan—observations from the prospective, multicenter Kyoto Congestive Heart Failure (KCHF) Registry. Circ J. 2018;82(11):2811–9.
doi: 10.1253/circj.CJ-17-1386
Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T, et al. 9-Year trend in the management of acute heart failure in japan: a report from the national consortium of acute heart failure registries. J Am Heart Assoc. 2018;7(18):e008687.
doi: 10.1161/JAHA.118.008687
Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, Committee ASA, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47(1):76–84.
doi: 10.1016/j.jacc.2005.09.022
Mizuno A, Iguchi H, Sawada Y, Hurley M, Nomura H, Hayashi K, et al. The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: high value care vs. low value care campaign in Japan. Int J Cardiol. 2017;241:243–8.
doi: 10.1016/j.ijcard.2017.04.078
Yasuda S, Nakao K, Nishimura K, Miyamoto Y, Sumita Y, Shishido T, et al. The current status of cardiovascular medicine in Japan—analysis of a large number of health records from a Nationwide Claim-Based Database. JROAD-DPC Circ J. 2016;80(11):2327–35.
doi: 10.1253/circj.CJ-16-0196
Nagai T, Iwakami N, Nakai M, Nishimura K, Sumita Y, Mizuno A, et al. Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: Insight from a nationwide claim-based database. Int J Cardiol. 2019;280:104–9.
doi: 10.1016/j.ijcard.2019.01.049
Kanaoka K, Okayama S, Nakai M, Sumita Y, Onoue K, Soeda T, et al. Number of cardiologists per cardiovascular beds and in-hospital mortality for acute heart failure: a nationwide study in Japan. J Am Heart Assoc. 2019;8(18):e012282.
doi: 10.1161/JAHA.119.012282
Konishi M, Matsuzawa Y, Ebina T, Kosuge M, Gohbara M, Nishimura K, et al. Impact of population density on mortality in patients hospitalized for heart failure—JROAD-DPC registry analysis. J Cardiol. 2020;75(4):447–53.
doi: 10.1016/j.jjcc.2019.09.008
Shiga T, Suzuki A, Haruta S, Mori F, Ota Y, Yagi M, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. ESC Heart Fail. 2019;6(3):475–86.
doi: 10.1002/ehf2.12418
JCS Joint Working Group. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). Circ J. 2014; 78(8):2022–93.
Medical Vision Data. https://www.mdv.co.jp/solution/pharmaceutical/english/ . Accessed 7 Nov 2019.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
doi: 10.1016/0895-4356(92)90133-8
Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(25):3042–51.
doi: 10.1016/j.jacc.2017.04.042
Aizawa H, Imai S, Fushimi K. Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database. BMC Cardiovasc Disord. 2015;15:134.
doi: 10.1186/s12872-015-0127-9
Sasaki N, Kunisawa S, Ikai H, Imanaka Y. Differences between determinants of in-hospital mortality and hospitalisation costs for patients with acute heart failure: a nationwide observational study from Japan. BMJ Open. 2017;7(3):e013753.
doi: 10.1136/bmjopen-2016-013753
Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J. 2013;77(4):944–51.
doi: 10.1253/circj.CJ-13-0187
Greene S, Triana T, Ionescu-Ittu R, Burne R, Guérin A, Borentain M, et al. In-hospital therapy for heart failure with reduced ejection fraction in the United States. JACC Heart Fail. 2020;8(11):943–53.
doi: 10.1016/j.jchf.2020.05.013
Sakamoto H, Rahman M, Nomura S, Okamoto E, Koike S, Yasunaga H, et al. Japan health system review. World Health Organization. Regional Office for South-East Asia. License: CC BY-NC-SA 3.0 IGO. Health Systems in Transition Vol. 8 No. 1 2018. https://apps.who.int/iris/handle/10665/259941 .
Goto Y. Current state of cardiac rehabilitation in Japan. Prog Cardiovasc Dis. 2014;56(5):557–62.
doi: 10.1016/j.pcad.2013.12.001
Nagai T, Sundaram V, Rothnie K, Quint JK, Shoaib A, Shiraishi Y, et al. Mortality after admission for heart failure in the UK compared with Japan. Open Heart. 2018;5(2):e000811.
doi: 10.1136/openhrt-2018-000811
Hashimoto H, Ikegami N, Shibuya K, Izumida N, Noguchi H, Yasunaga H, et al. Cost containment and quality of care in Japan: is there a trade-off? Lancet. 2011;378(9797):1174–82.
doi: 10.1016/S0140-6736(11)60987-2
McKee SP, Leslie SJ, LeMaitre JP, Webb DJ, Denvir MA. Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians. Eur J Heart Fail. 2003;5(4):549–55.
doi: 10.1016/S1388-9842(03)00003-5
Hoorn C, Crijns H, Dierick-van Daele A, Dekker L. Review on factors influencing physician guideline adherence in cardiology. Cardiol Rev. 2019;27(2):80–6.
doi: 10.1097/CRD.0000000000000207
Matsue Y, Kagiyama N, Yoshida K, Kume T, Okura H, Suzuki M, et al. Carperitide is associated with increased in-hospital mortality in acute heart failure: a propensity score-matched analysis. J Card Fail. 2015;21(11):859–64.
doi: 10.1016/j.cardfail.2015.05.007
Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72(11):1787–93.
doi: 10.1253/circj.CJ-08-0130
The Japanese Circulation Society/The Japanese Heart Failure Society: Statement of proper use of vasopressin V2 receptor antagonist (Japanese). 2013. https://asas.or.jp/jhfs/pdf/20131021_statement.pdf (asas.or.jp).
Shirakabe A, Hata N, Yamamoto M, Kobayashi N, Shinada T, Tomita K, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J. 2014;78(4):911–21.
doi: 10.1253/circj.CJ-13-1255